Stop TB Partnership calls US$18 billion from global leaders’ meeting in New York to end TB

By Prosper Makene

Dr Lucica Ditiu, Executive Director of Stop TB Partnership

The Stop TB Partnership calls on donors and governments of high-burden tuberculosis (TB) countries to pledge at least US$18 billion to the Global Fund and to triple domestic investments in TB.

On her statement during the eve of the Global Fund’s Seventh Replenishment Conference, Dr. Lucica Ditiu, Executive Director of the Stop TB Partnership said:

“Pledges to end TB by 2030 increasingly appear to be pipe dreams at this point. In this context, we urge global leaders meeting in New York City for the Global Fund to Fight ’s Seventh Replenishment and the UN General Assembly to increase funding that will be essential to drive us towards ending TB and other deadly infectious diseases.

“At the same time, we must recognize that US$18 billion for the  Global Fund’s Seventh Replenishment represents the minimum for the TB response, as this replenishment figure will secure around US$1.2 billion per year for TB versus a need from the Global Fund which should ideally be four times higher—in addition to the need for domestic budgets for TB to dramatically increase.

“Of the three global diseases that the Global Fund tackles, TB—which is airborne and poses a risk for everyone that breathes—continues to kill more people than HIV/AIDS and malaria combined. And even though TB has been supplanted by COVID-19 as the world’s deadliest infection, people infected with TB have fared much worse during the pandemic.

“An estimated 1.5 million people died of TB in 2020—the first increase in TB deaths in more than a decade. The figures are probably higher, as we don’t have exact numbers because almost 40% of all people with TB disease are ‘missed’—undiagnosed and untreated or simply not recorded by the health systems.

“Despite the surge in disease, governments spent US$500 million less on TB in 2020. Considering that the world was spending less than half of the funds needed for TB diagnostic, treatment and prevention services even before the COVID-19 pandemic hit, this additional decrease has been catastrophic.

“TB cannot continue to be an orphan disease in the global health world, especially now when the world saw how unprepared it was to fight an airborne disease—and how important the TB systems, staff and platforms were in fighting the COVID pandemic. We cannot accept anymore that despite the many global and regional pledges to increase funding and efforts to end TB, people suffering from this ancient disease are still forgotten.”


In 2020, about 1.5 million people died from TB, more than HIV/AIDS (680,000 deaths in 2020) and malaria (627,000 deaths in 2020) combined.

In July 2022, the Stop TB Partnership released the Global Plan to End TB 2023-2030, outlining the priority actions and estimated financial resources needed to end TB as a global health threat by 2030. It laid out how, from now up to 2030, a global investment of US$250 billion was needed to save millions of lives through early diagnosis and treatment of 50 million people with TB; the development, approval and distribution of a new TB vaccine; and the redoubling of efforts to address emerging crises like the COVID-19 pandemic or conflicts.

At its Seventh Replenishment Pledging Conference, the Global Fund to End HIV, TB and Malaria aims to mobilize US$18 billion to save 20 million lives. The conference will take place in New York City on September 19-21, 2022. At the November 2021 meeting, the Global Fund’s board agreed to divide up its programmatic funding for 2023-2025 as follows:

Any available funds for country allocation up to and including US$12 billion will be apportioned as follows:

50% for HIV/AIDS.

18% for Tuberculosis.

32% for Malaria.

Any additional available funds for country allocation above US$12 billion will be apportioned as follows:

45% of such funds will be apportioned to HIV/AIDS.

25% of such funds will be apportioned to Tuberculosis.

30% of such funds will be apportioned to Malaria.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button